vTv to propose path forward for AD candidate despite Phase III miss

vTv Therapeutics Inc. (NASDAQ:VTVT) said azeliragon (TTP488) missed the co-primary endpoints compared with placebo in Part B of the Phase III STEADFAST trials to treat mild Alzheimer’s disease. Despite the miss, the company said it plans to meet with FDA to propose a path forward for azeliragon based on pooled data from a subgroup of patients.

In April, vTv said it would discontinue clinical trials of the oral small molecule receptor for advanced glycation endproducts (RAGE) antagonist after the product missed the co-primary endpoints in Part A of STEADFAST (see BioCentury, April 13)...